Intracellular bacteria are poorly responsive to antibiotic treatment. Pharmacological studies are thus needed to determine the antibiotics which are the most potent or effective against intracellular bacteria as well as to explore the reasons for poor bacterial responsiveness. An in vitro pharmacodynamic model is described, consisting of (i) phagocytosis of pre-opsonized bacteria by eukaryotic cells; (ii) elimination of non-internalized bacteria with gentamicin; (iii) incubation of infected cells with antibiotics; (iv) determination of surviving bacteria by viable cell counting and normalization of the counts based on sample protein content.
Introduction
Intracellular survival of bacteria is now recognized as a major factor associated with dissemination, persistence or recurrence of infections (1) (2) (3) (4) (5) . When residing inside eukaryotic cells, bacteria are indeed protected from the host humoral immune defenses and often adopt a dormant lifestyle less responsive to antibiotic action.
Moreover, in order to exert their activity against intracellular bacteria, antibiotics have to gain access to the infected compartment within the cells and to express their activity in this specific environment (6, 7) . For these reasons, intracellular activity of antibiotics is unpredictable based on the simple evaluation of their activity against extracellular bacteria in broth and of their accumulation within eukaryotic cells.
Appropriate models need to be developed for the correct assessment of the capacity of antibiotics to act upon intracellular bacteria.
We present here an in vitro model which allows studying the pharmacodynamics of antibiotics against intracellular bacteria. This model is highly flexible, being adaptable to several bacterial species or strains (8) (9) (10) (11) as well as to many cell types (9, 12, 13) . It has been used to compare the activity of commercially available antibiotics (11, 14) and of molecules in preclinical or clinical development (most of which are now registered or in the late phases in clinical trials; 9, 12, [15] [16] [17] [18] [19] , with the aim of predicting their potential interest for the treatment of persistent infections. In the case of Staphylococcus aureus infections, it has been validated vs. animal models of intracellular infection (20, 21) .
Materials

Equipment
1. Laminar flow hood : work is performed in a laminar flow hood in a room with biosafety level adapted to the pathogenicity of the microorganism under investigation (22 9. Reagents (see Note 2) or kit for cell viability assay (trypan blue exclusion assay [24] or release of the cytosolic enzyme lactate dehydrogenase [25] , for example).
Methods
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The method described is illustrated in Fig.1 . INSERT FIG.1. 
Preparation of bacterial suspension and of media
1. The day before the experiment, prepare an overnight bacterial culture in 15 mL of MHB (37°C ; agitation) to obtain a stationary phase culture.
2. Unfreeze human serum.
3. Prewarm culture medium, sterile water, and PBS at 37°C.
Opsonization of bacteria
Opsonization is a process by which bacteria are marked by opsonins, which are serum proteins (like antibodies) bridging bacteria to the cell surface in order to favor phagocytosis (see Note 3).
1.
Centrifuge the overnight culture to pellet bacteria (7 minutes at 3200 g).
2.
Resuspend in 1 mL of human serum; dilute with 9 mL of eukaryotic cell culture medium (not supplemented with fetal calf serum in this case, since human serum [final concentration 10%] is present). Do not vortex.
3.
Incubate for 30-60 minutes at 37°C under gentle agitation (130 rpm) (11, 26) .
Preparation of eukaryotic cells and bacteria for infection
1. If using eukaryotic cells in suspension, count them (for example using a hemocytometer) in order to obtain a density of 500,000 to 750,000 cells/mL (see
Note 4).
2. If using adherent cells, plate them in multi-well plates. They should have reached 80 % confluence at the time of the experiment. Prepare extra wells to be used for cell counting at the time of the infection. 
Phagocytosis
This step is critical, in the sense that it is specific for each bacterial strain or species (8, 11, 14, 27) and for the cell type to use for infection (9, 12, 13, 15) and should be adapted by the experimenter (see Fig. 2 ). The objective is to obtain after phagocytosis an intracellular inoculum that is high enough to allow further growth of the bacteria but low enough to avoid killing the host cells (typically 10 6 cfu/mg cell protein). The general principle of this part of the protocol is explained hereafter. 
Eliminate non phagocytized bacteria either by centrifugation (cells in suspension;
7 minutes; 340 g) or by elimination of the medium (adherent cells).
3. Re-incubate infected cells during 45-60 minutes (37°C; CO 2 incubator) in cell culture medium (without serum) containing gentamicin at high concentration (typically 50-100 times the MIC for the bacterial strain used [11, 14] ) in order to eliminate non-phagocytized bacteria that may adhere to the cell surface (see
Note 5).
4. Wash three times with PBS at room temperature to eliminate bacterial debris and gentamicin.
5. Collect infected cells in 1 ml of sterile water in order to lyse them and allow for release of phagocytized bacteria.
6. Prepare logarithmic dilutions of the cell lysates in PBS and plate 50 µL on TSA or any other appropriate agar plate; proceed to colony counting after 24 h incubation.
7. In parallel, determine protein content of the cell lysates by the Folin-Ciocalteu method (23), using a commercial kit or the method described in Note 1.
8. Express the data as cfu/mg of cell protein and select for further experiments the conditions for which you obtain approx. 10 6 cfu/mg cell protein (see Note 6).
Intracellular growth
1. Re-incubate the infected cells in cell culture medium supplemented with 10 % fetal calf serum. For control conditions, add gentamicin at a concentration close to the MIC (as measured in the culture medium used for the experiment) to avoid extracellular growth (see Fig. 2 ) and, in case of cell killing, release of a small number of bacteria into the medium (14) . For experimental conditions, add the
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antibiotic you wish to test at the appropriate concentration in the culture medium (see Notes 7 and 8).
2. At the end of the incubation period, wash the cells three times in PBS and collect them in sterile distilled water as explain above. Proceed to plating, cfu counting and protein assay.
Assessment of antibiotic intracellular activity
The model described here allows to monitor antibiotic activity against intracellular bacteria over time or as a function of the extracellular concentration of the antibiotic (11,14).
1. Considering time effects, bacterial growth is often delayed inside the cells (lag phase of a few hours), so that bacterial killing by antibiotics occurs slower than in broth.
2. Considering concentration effects, performing experiments with broad ranges of extracellular concentrations (from sub-MIC values to many times the MIC) allows obtaining full concentration-response curves for fitting with sigmoid regressions (see Fig. 3 ).
3. Using the corresponding Hill's equation, key pharmacological descriptors of activity can be calculated.
• The relative minimal efficacy [Emin; in log 10 cfu units], i.e. the increase in the number of cfu for an infinitely low antibiotic concentration compared to the original post-phagocytosis inoculum.
• The relative maximal efficacy [E max ; in log 10 cfu units], i.e. the decrease in the number of cfu for an infinitely large concentration of antibiotic.
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• The relative potency [EC 50 ; in mg/L or in multiples of MIC], i.e. the concentration of antibiotic yielding a response half-way between E min and E max .
• The static concentration [C s ; in mg/L or in multiple of MIC], i.e. the concentration of antibiotic resulting in no apparent bacterial growth compared to the original inoculum (10).
4.
Two major observations have been made with this type of model (see Fig. 3 ).
• First, the static concentration against intracellular bacteria (i.e. the antibiotic concentration preventing bacterial growth) is in most cases close to the MIC, suggesting that the potency of the drug is not directly correlated with its accumulation inside the cells, possibly because of poor intracellular bioavailability.
• Second, the antibiotic maximal efficacy is in most cases much lower against intracellular bacteria than against extracellular bacteria, 
Notes
1. Protein assay can be performed without any commercial kit, using the protocol described by Lowry (23) . Reagents required are Biuret reagent (extemporaneous mixture of 100 mL 2% Na 2 CO 3 , 1 mL 2% potassium sodium tartrate, 1 mL 1% CuSO 4 .5H 2 O), 2N Folin-Ciocalteu reagent (diluted to 1N), 1N NaOH, and a standard (100 µg/mL bovine albumin). In brief, 0.5 mL of cell lysate (or dilution thereof), blank (medium in which cells were collected),
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Van 3. When using obligatory or facultative intracellular organisms which are specifically equipped to use the serum complement to increase phagocytosis, opsonization causes massive infection of the cells (28) . Pre-opsonization is therefore not systematically required (27) and, alternatively, culture medium could be supplemented with decomplemented serum or calf serum (heated for 30 minutes at 56°C; [29] ) to reduce phagocytosis in order to reach postphagocytosis inocula compatible with maintenance of cell viability for 24 h. 
